These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 35884517)

  • 1. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies.
    Griffioen MS; de Leeuw DC; Janssen JJWM; Smit L
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia.
    Pelosi E; Castelli G; Testa U
    Mediterr J Hematol Infect Dis; 2022; 14(1):e2022080. PubMed ID: 36425147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax.
    Wang YW; Tsai CH; Lin CC; Tien FM; Chen YW; Lin HY; Yao M; Lin YC; Lin CT; Cheng CL; Tang JL; Chou WC; Hou HA; Tien HF
    Ann Hematol; 2020 Mar; 99(3):501-511. PubMed ID: 31965269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.
    Zhang LS; Wang J; Xu MZ; Wu TM; Huang SM; Cao HY; Sun AN; Liu SB; Xue SL
    Onco Targets Ther; 2022; 15():159-164. PubMed ID: 35221695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
    Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
    Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
    Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
    Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Relapsed Acute Myeloid Leukemia.
    Thol F; Ganser A
    Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
    Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
    Seipel K; Mandhair H; Bacher U; Pabst T
    Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience.
    Piccini M; Pilerci S; Merlini M; Grieco P; Scappini B; Bencini S; Peruzzi B; Caporale R; Signori L; Pancani F; Vannucchi AM; Gianfaldoni G
    J Clin Med; 2021 Apr; 10(8):. PubMed ID: 33919958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2 inhibitor synergizes with PI3Kδ inhibitor and overcomes FLT3 inhibitor resistance in acute myeloid leukaemia.
    Yao MY; Wang YF; Zhao Y; Ling LJ; He Y; Wen J; Zheng MY; Jiang HL; Xie CY
    Am J Cancer Res; 2022; 12(8):3829-3842. PubMed ID: 36119822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DRP1 Inhibition Enhances Venetoclax-Induced Mitochondrial Apoptosis in TP53-Mutated Acute Myeloid Leukemia Cells through BAX/BAK Activation.
    Jang JE; Hwang DY; Eom JI; Cheong JW; Jeung HK; Cho H; Chung H; Kim JS; Min YH
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.
    Huemer F; Melchardt T; Jansko B; Wahida A; Jilg S; Jost PJ; Klieser E; Steiger K; Magnes T; Pleyer L; Greil-Ressler S; Rass C; Greil R; Egle A
    Eur J Haematol; 2019 May; 102(5):437-441. PubMed ID: 30725494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
    DiNardo CD; Tiong IS; Quaglieri A; MacRaild S; Loghavi S; Brown FC; Thijssen R; Pomilio G; Ivey A; Salmon JM; Glytsou C; Fleming SA; Zhang Q; Ma H; Patel KP; Kornblau SM; Xu Z; Chua CC; Chen X; Blombery P; Flensburg C; Cummings N; Aifantis I; Kantarjian H; Huang DCS; Roberts AW; Majewski IJ; Konopleva M; Wei AH
    Blood; 2020 Mar; 135(11):791-803. PubMed ID: 31932844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia.
    Báez-Gutiérrez N; Rodríguez-Ramallo H; Moreno MA; Arboli ER; Abdel-Kader Martín L
    Ther Adv Hematol; 2021; 12():20406207211040335. PubMed ID: 34471510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.